The group published a position statement today advocating for "extensive" sharing of lab and clinical data in order to improve treatment of patients.
The recommendations were developed by a working group of the AMP Clinical Practice Committee that included representatives from ACMG, ASCO, and CAP.
An ACMG workgroup has added four new genes, removed one gene, and said it would open up the nomination process to the broader community and consider PGx genes.
In a new AMP working group project, labs can volunteer to compare their interpretation of challenging variants to help identify where and how the guidelines might be improved.
The revisions, which are subject to approval by the ACMG board of directors, will likely involve the addition of five genes and the removal of one gene from the list.
The foundation, which was established by the American College of Medical Genetics and Genomics, will use the money to fund fellows' salaries and research.
In a pilot study published in AJHG, nine labs initially agreed for only 34 percent of variants, but for 71 percent after discussing the evidence and use of guidelines in detail.
For many patients, the diagnosis led to a change in medical care or management, averted additional diagnostic tests, and facilitated family planning.
A genetic testing utilization service launched by Stanford in 2015 helped cut the number of inappropriately ordered tests in half and saved about $250,000 during the first year.
Magdalena Walkiewicz from Baylor College of Medicine and Carin Yates from GeneDx presented their labs' initial findings from exome sequencing of fetal DNA samples.
In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.
Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.
HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.
Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.